In a report released today, Ed Arce from H.C. Wainwright maintained a Hold rating on Avenue Therapeutics (ATXI), with a price target of $6.00. The company’s shares closed last Friday at $6.29.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 17.3% and a 40.4% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Aurinia Pharmaceuticals.
Currently, the analyst consensus on Avenue Therapeutics is a Moderate Buy with an average price target of $9.00.
See today’s analyst top recommended stocks >>
The company has a one-year high of $12.34 and a one-year low of $2.85. Currently, Avenue Therapeutics has an average volume of 525.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Avenue Therapeutics, Inc. engages in acquiring, licensing, developing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, which is intended for the treatment of moderate to moderately severe post-operative pain. The company was founded on February 9, 2015 and is headquartered in New York, NY.
